An Update on IL-22 Therapies in Alcohol-Associated Liver Disease and Beyond
- 18 April 2025
- journal article
- review article
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (1) , 136-150
Abstract
No abstract availableKeywords
Funding Information
- Servier
- National Institute on Alcohol Abuse and Alcoholism (1Z1AAA000375-19)
This publication has 132 references indexed in Scilit:
- Diagnosis and Management of Cirrhosis and Its ComplicationsJAMA, 2023
- Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use DisorderJAMA Network Open, 2022
- IL‐22‐mediated renal metabolic reprogramming via PFKFB3 to treat kidney injuryClinical and Translational Medicine, 2021
- Alcohol‐Associated Liver Disease: East Versus WestClinical Liver Disease, 2020
- Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL‐22Fc): A Potential Therapy for Epithelial InjuryClinical Pharmacology & Therapeutics, 2018
- Short‐ or long‐term high‐fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: An important role for CXCL1Hepatology, 2015
- Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in miceHepatology, 2012
- Enteric dysbiosis associated with a mouse model of alcoholic liver diseaseHepatology, 2010
- Interleukin-22 Treatment Ameliorates Alcoholic Liver Injury in a Murine Model of Chronic-Binge Ethanol Feeding: Role of Signal Transducer and Activator of Transcription 3Hepatology, 2010
- Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activationHepatology, 2004